Evidence map›Paper›PMID 28786218›Full record

ArticleClinical pharmacology and therapeutics2018

Response to "Impact of CYP3A4 Genotype on Voriconazole Exposure: New Insights Into the Contribution of CYP3A4*22 to Metabolism of Voriconazole".

Thomas J Walsh, Brad Moriyama, Scott R Penzak, Teri E Klein, Kelly E Caudle

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in Clinical pharmacology and therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Cannabis Pharmacogenomics: A Path to Personalized Medicine.Current issues in molecular biology · 2023
    Review
  2. Review
  3. Osteoarticular Mycoses.Clinical microbiology reviews · 2022
    Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 1 country.

Thomas J WalshTransplantation - Oncology Infectious Diseases, Departments of Medicine, Pediatrics, and Microbiology and Infectious Diseases, Weill Cornell Medical Center of Cornell University, New York, New York, USA.
Brad MoriyamaNational Institutes of Health (NIH) Clinical Center, Pharmacy Department, Bethesda, Maryland, USA.
Scott R PenzakDepartment of Pharmacotherapy, University of North Texas, System College of Pharmacy, Fort Worth, Texas, USA.
Teri E KleinDepartment of Biomedical Data Science, Stanford University, Stanford, California, USA.
Kelly E CaudleDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Cornell University · USNational Institutes of Health Clinical Center · USStanford University · USSt. Jude Children's Research Hospital · USUniversity of North Texas System · US

Funding

PharmGKB: pharmacogenomics knowledge for precision medicineR24GM061374 · NIGMS · STANFORD UNIVERSITY · PI ALTMAN, RUSS BIAGIO, KLEIN, TERI ELLEN · 2010 to 2018
$25.2M
NIGMS NIH HHS R24 GM061374
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antifungal AgentsPharmacogeneticsCytochrome P-450 CYP2C19Cytochrome P-450 CYP3AGenotypeVoriconazoleAntifungal AgentsCytochrome P-450 CYP2C19Cytochrome P-450 CYP3AVoriconazole

Identifiers

PMID28786218
OpenAlexW2743359098

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.